DerrickSHaslemMD

Oncology • Saint George, UT

Physician

Join to view full profile

Dr. Haslem is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haslem's full profile

Already have an account?

Office
544 S 400 E
Saint George, UT 84770
Phone+1 435-688-4900

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 2007 - 2009
University of Utah HealthResidency, Internal Medicine, 2004 - 2007
University of Utah School of MedicineClass of 2004

Certifications & Licensure

AZ State Medical License 2020 - 2026
MT State Medical License 2020 - 2026
UT State Medical License 2005 - 2026
CO State Medical License 2020 - 2025
ID State Medical License 2017 - 2025
NV State Medical License 2020 - 2025
WY State Medical License 2018 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

The single-cell spatial landscape of stage III colorectal cancers.
Andrew Su, HoJoon Lee, Minh Tran, Richard D Cruz, Anuja Sathe
Biorxiv. 2024-11-11
4 citations
The Development of an Infrastructure to Facilitate the Use of Whole Genome Sequencing for Population Health.
Nephi A Walton, Brent Hafen, Sara Graceffo, Nykole Sutherland, Melanie Emmerson
Journal of Personalized Medicine. 2022-11-08
4 citations
Germline variants of ATG7 in familial cholangiocarcinoma alter autophagy and p62.
Stephanie U Greer, Jiamin Chen, Margret H Ogmundsdottir, Carlos Ayala, Billy T Lau
Scientific Reports. 2022-06-20

Press Mentions

‘The Future of Cancer Care Really Is Bright’: Virtual Jubilee of Trees Benefits Cancer Care, HerediGene StudyNovember 18th, 2020
Jubilee of Trees Goes Virtual, Benefits Cancer Care at Dixie Regional Medical CenterNovember 13th, 2020
Intermountain Cancer Center to Open in St. GeorgeJanuary 3rd, 2019
Join now to see all

Other Languages

Spanish